Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
DNLI
SELLDenali Therapeutics Inc. · Healthcare · United States · $3.7B · Avg Vol: $46M/d
COMPANY DESCRIPTION
Denali Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. Its competitive advantage lies in its proprietary scientific platforms, including its "Transport Vehicle" technology designed to enable drugs to cross the blood-brain barrier effectively. The company maintains a focused pipeline and strategic partnerships, positioning itself as a leader in addressing challenging neurological conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 108.5M | 330.5M | 0 | 0 | 204.7% | — | 34.0M | 103.7M | -25.2% |
| EPS | -2.60 | -1.06 | -2.57 | -2.97 | — | -2.83 | -2.37 | -2.53 | — |
| Shares | 136.0M | 138.4M | 144.2M | 156.2M | +14.9% | 158.7M | — | — | — |
| Debt | 60.4M | 52.2M | 48.7M | 36.8M | -15.2% | 40.0M | — | — | — |
| Equity | 1.0B | 1.0B | 1.2B | 1.0B | -0.9% | — | — | — | — |
| Op CF | -244.7M | -358.0M | -347.7M | -412.6M | — | -412.3M | — | — | — |
| Inv CF | -141.4M | 249.3M | -88.8M | 255.3M | — | — | — | — | — |
| Fin CF | 310.7M | 17.8M | 484.3M | 189.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DNLI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DNLI | Denali Therapeutics Inc.(you) | $3.7B | 26 | SELL |
| ALMS | Alumis Inc. | $3.6B | 22 | SELL |
| RCUS | Arcus Biosciences, Inc. | $3.6B | 22 | SELL |
| LEGN | Legend Biotech Corporation | $4.3B | 24 | SELL |
| CAI | Caris Life Sciences, Inc. | $4.4B | 27 | SELL |
| IDYA | IDEAYA Biosciences, Inc. | $3.4B | 29 | SELL |
| VKTX | Viking Therapeutics, Inc. | $4.0B | 21 | SELL |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.6B | 26 | SELL |
| TNGX | Tango Therapeutics, Inc. | $4.3B | 29 | SELL |
| CLDX | Celldex Therapeutics, Inc. | $2.8B | 24 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%